POM-V Prescription Required

Equip WNV Emulsion for Injection for Horses

Active ingredient: West Nile virus

Form

Injection

Species

Horses

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5023

What it's used for

For the active immunisation of horses of 6 months of age or older against West Nile virus (WNV) disease by reducing the number of viraemic horses after inf...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for West Nile virus

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Equip WNV Emulsion for Injection for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the active immunisation of horses of 6 months of age or older against West Nile
virus (WNV) disease by reducing the number of viraemic horses after infection with
WNV lineage 1 or 2 strains and to reduce duration and severity of clinical signs
against WNV of lineage 2 strains.
Onset of immunity: 3 weeks after primary vaccination course.
Duration of immunity: 12 months after primary vaccination course for WNV lineage 1
strains. For WNV lineage 2 strains the duration of immunity has not been
established.

None

Revised: January 2025
AN: 02728/2024

Horses:
Rare
(1 to 10 animals / 10,0000 animals
treated):
Hypersensitivity reaction
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports)
Hyperthermia
Injection site swelling (sometimes
associated with injection site pain and
mild depression)
1
As with any vaccine rare, occasional hypersensitivity reactions may occur. If such a
reaction occurs, appropriate treatment should be administered without delay.
Resolves within 2 days
Transient local reactions in the form of a mild, local swelling at the injection site post
vaccination (maximum 1 cm in diameter) that resolve spontaneously within 1 to 2
days.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for contact details.

Revised: January 2025
AN: 02728/2024

Vaccinate healthy animals only.

Special precautions for use in animals
Vaccination may interfere with existing sero-epidemiological surveys. However, since
the IgM response following vaccination is infrequent, a positive IgM-ELISA test result
is a strong indicator of natural infection with West Nile virus. If infection is suspected
as a result of a positive IgM response, additional testing would need to be conducted
to conclusively determine whether the animal was infected or vaccinated.
No specific studies have been conducted to demonstrate absence of interferences
from maternally derived antibodies on vaccine take. It is therefore recommended not
to vaccinate foals of less than 6 months of age.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.
Protect from light.

*Relative potency by in vitro method, compared to a reference vaccine that was
shown efficacious in horses.
For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.